Inhibrx reported positive registrational Phase 2 results for ozekibart (INBRX‑109) in unresectable or metastatic chondrosarcoma, meeting the primary endpoint with a statistically significant improvement in progression‑free survival. The data moved Inhibrx to plan a biologics license application (BLA) submission in the second half of 2026. The readout addresses an area of high unmet need where few therapies exist and may support accelerated regulatory pathways. Inhibrx’s stock reacted strongly to the topline, and the company signaled broader development in other hard‑to‑treat tumors, leveraging its monoclonal antibody platform.